Literature DB >> 17407088

[ssociation of HLA class I and II alleles with generalized vitiligo in Chinese Hans in north China].

Jun Wang1, Yu-ming Zhao, Yan Wang, Yi Xiao, Ya-kun Wang, Hong-duo Chen.   

Abstract

OBJECTIVE: To investigate the association of HLA class I and II alleles with generalized vitiligo in ethnic Han Chinese in north China.
METHODS: By employing polymerase chain reaction sequence-specific primer (PCR-SSP) procedure 34 generalized vitiligo patients in north China were studied for HLA I and II alleles and were compared with 102 healthy controls.
RESULTS: The allelic frequencies of HLA-A*30, Cw*06, DRB1*07, and DQB1*0201 were increased significantly in generalized vitiligo and especially in the patients without family history compared with the controls.
CONCLUSION: These alleles positively associated with generalized vitiligo in Chinese Han patients in north China, might provide clues to reveal the susceptibility gene(s) of vitiligo in Chinese and as well as the immunnogenetic mechanisms of disease.

Entities:  

Mesh:

Year:  2007        PMID: 17407088

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi        ISSN: 1003-9406


  3 in total

1.  The association between a single nucleotide polymorphism rs11966200 in MHC region and clinical features of generalized vitiligo in Chinese Han population.

Authors:  Jin Tang; Jian Lan Liu; Cheng Zhang; Da Yan Hu; Su Min He; Xian Bo Zuo; Pei Guang Wang; Liang Dan Sun; Xue Jun Zhang; Sen Yang
Journal:  Mol Biol Rep       Date:  2013-03-21       Impact factor: 2.316

Review 2.  Vitiligo--part 1.

Authors:  Roberto Gomes Tarlé; Liliane Machado do Nascimento; Marcelo Távora Mira; Caio Cesar Silva de Castro
Journal:  An Bras Dermatol       Date:  2014 May-Jun       Impact factor: 1.896

Review 3.  Meta-Analysis of the Association between Vitiligo and Human Leukocyte Antigen-A.

Authors:  Zhangjun Li; Jianwen Ren; Xinwu Niu; Qingqiang Xu; Xiaopeng Wang; Yale Liu; Shengxiang Xiao
Journal:  Biomed Res Int       Date:  2016-09-05       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.